论文部分内容阅读
腹水是肝硬化由代偿期转为失代偿期一个重要标志。约50%的代偿性肝硬化患者10年内都将发生腹水,腹水患者比非腹水患者发生食管静脉曲张破裂出血的概率多3倍,如不接受肝移植治疗,2年内死亡率可达50%。而顽固性腹水因其诱发电解质紊乱、肝性脑病、肝肺综合征及肝肾综合征等,使患者的症状改善及生活质量较差,死亡率和复发率较高。西医在治疗难治性腹水方面往往采用大量腹腔放水联合白蛋白输注、自身腹水浓缩回输、经颈静脉门-体分流术、腹腔-颈静脉分流术及肝移植等
Ascites is an important indicator of cirrhosis from decompensation to decompensation. About 50% of patients with compensated cirrhosis will develop ascites within 10 years. Patients with ascites have 3 times more likely to have esophageal variceal bleeding than non-ascites patients. If they do not receive liver transplantation, their death rate will reach 50% . The refractory ascites induced electrolyte imbalance, hepatic encephalopathy, hepatopulmonary syndrome and hepatorenal syndrome, so that patients with improved symptoms and poor quality of life, higher mortality and relapse. Western medicine in the treatment of refractory ascites often use a large number of abdominal drainage combined with albumin infusion, its own ascites concentration back, transjugular jugular shunt, peritoneal-jugular shunts and liver transplantation